article thumbnail

BenchSci raises $50m to grow AI-powered R&D platform

pharmaphorum

The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving reagent and antibody selection to help scientists run more successful experiments, drawing on data from published studies and organisations’ internal databases.

article thumbnail

Yale-NBA Partnership Results in FDA Approval for COVID-19 SalivaDirect Test

XTalks

Instead of RNA extraction, the Yale test involves use of a reagent that when mixed with a saliva sample and heated for a short period of time, releases the viral genome for subsequent detection with PCR. Having a test that requires less reagents and resources, such as the RNA extraction kits, increases capabilities for increased testing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

As life science operates globally, the vision for the business was always to bring aptamers as an antibody alternative to researchers worldwide. Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies. Optimer binders are engineered to overcome these problems.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Moreover, Dr. Lin explains that in an academic lab, you are supposed to do everything – from ordering reagents, to washing dishes to doing an in vitro study for a project and then the in vivo work, through to completion. But in companies, you cannot do that. Funding in the Life Science Industry vs. Academia.